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BACKGROUND: Hepatitis B virus X protein (HBx) is involved in the initiation and progression of hepatocellular carcinoma (HCC) by
regulating the host protein-coding genes. In this study, we showed that HBx altered the expression of microRNAs (miRNAs) to
promote proliferation and transformation in malignant hepatocytes in vitro.
METHODS: miRNA microarray and quantitative reverse-transcription polymerase chain reactions (qRT-PCRs) were performed to
identify miRNAs that were differentially regulated by HBx in HCC cells. Protein, mRNA, and miRNA expression analyses; cell cycle
and apoptosis analyses; loss/gain-of-function analysis; and luciferase reporter assays were performed to delineate the consequences of
miR-16 family repression in HepG2 cells.
RESULTS: Hepatitis B virus X protein induced widespread deregulation of miRNAs in HepG2 cells, and the downregulation of the
miR-16 family was reproducible in HepG2, SK-HEP-1, and Huh7 cells. CCND1, a target of the miR-16 family, was derepressed by HBx
in HepG2 cells. c-Myc mediated the HBx-induced repression of miR-15a/16 in HepG2 cells. Ectopically expressed miR-15a/16
suppressed the proliferation, clonogenicity, and anchorage-independent growth of HBx-expressing HepG2 cells by arresting them in
the G1 phase and inducing apoptosis, whereas reduced expression of miR-16 accelerated the growth and cell-cycle progression of
HepG2 cells.
CONCLUSIONS: Hepatitis B virus X protein altered the in vitro expression of miRNAs in host malignant hepatocytes, particularly
downregulating the miR-16 family. Repression of miR-15a/16 is c-Myc mediated and is required for the HBx-induced transformation
of HepG2 cells in vitro. Therefore, miR-16 family may serve as a therapeutic target for hepatitis B virus (HBV)-associated HCC.
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Chronic hepatitis B virus (HBV) infection is the leading cause of
hepatocellular carcinoma (HCC) in Asia and West Africa (El-Serag
and Rudolph, 2007). In addition, HBV-infected HCCs exhibit more
aggressive biological characteristics during clinical disease progres-
sion than do non-infected tumours. Hepatitis B virus X protein
(HBx), an oncoprotein encoded by HBV, has been confirmed to
have a role in HBV-related hepatocarcinogenesis (Arbuthnot et al,
2000). It is a transactivating protein that alters host gene expression
by constitutively activating cytoplasmic signal transduction path-
ways (e.g., NF-kB, Src, Ras, AP-1, AP-2, PI3K/Akt, Jak/STAT, Smad,
and Wnt) and by binding to nuclear transcription factors (e.g.,
CREB, ATF-2, Oct-1, TBP, and basal transcription factors),
contributing to increased cell proliferation and survival (Feitelson
and Lee, 2007). It has been reported that HBx expression promotes
HCC in mice (Kim et al, 1991; Terradillos et al,1 9 9 7 )a n di n d u c e s
hepatocyte transformation in culture (Seifer et al,1 9 9 1 ) .
Increasing evidence has demonstrated that non-coding RNAs
(ncRNAs) are a new class of functional transcripts in eukaryotic
cells (Costa, 2005), including microRNAs (miRNAs), which are
21- to 23-nucleotide RNA molecules that regulate the stability or
translational efficiency of target mRNAs (Bartel, 2009). Primary
miRNA transcripts (pri-miRNAs) are sequentially processed by
two RNase III enzymes, Drosha and Dicer, to yield mature miRNAs
(Kim, 2005). microRNAs are deregulated in many human diseases,
especially in tumourigenesis. The pattern of miRNA expression
can be correlated with cancer type, stage, and other clinical
variables. microRNA expression analyses have also suggested
oncogenic (or tumour-suppressive) roles of miRNAs. Of note,
miRNAs have roles in almost all aspects of cancer biology, such as
proliferation, apoptosis, invasion/metastasis, and angiogenesis
(Lee and Dutta, 2009). The location of miRNAs in cancer-
associated genomic regions, epigenetic mechanisms, and altera-
tions in the miRNA processing machinery all contribute to the
widespread differential expression of miRNA genes in malignant
cells compared with normal cells (Calin and Croce, 2006).
Recently, miRNAs have been confirmed to function in viral
pathogenesis by regulating the expression of genes from both the
viral and host genomes. Epstein-Barr virus (EBV) encodes its own
miRNAs, whereas its oncoprotein, LMP-1, induces the expression
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the innate immune response to the virus-infected host cell (Motsch
et al,2 0 0 7 ) .S i m i l a r l y ,h u m a nT - l y m p h o t r o p i cv i r u st y p eI( H T L V - 1 )
transforms host cells by inducing dysregulation of the expression
of specific miRNAs, including miR-146a, which is upregulated by
Tax (an oncoprotein of HTLV-1) (Pichler et al, 2008). Further-
more, miR-193b expression is induced by the hepatitis C virus
(HCV), and this expression facilitates chemosensitivity to sorafenib
in malignant hepatocytes (Braconi et al, 2010).
In this study, we first hypothesised that HBx expression in
hepatocytes would alter host cellular miRNA expression, leading to
HCC initiation and progression. We identified the significantly
changed miRNAs (42-fold) between HepG2-hbx and HepG2-vc
cells via microarray. The expression of HBx caused widespread
miRNA repression in HepG2 cells, including the miR-16 family.
Members of this family are frequently downregulated in multiple
haematopoietic and solid tumours, including HCC (Huang et al,
2009), and this prompted us to further research regarding their
repression. Downregulation of the miR-16 family was validated by
quantitative reverse-transcription polymerase chain reaction
(qRT-PCR) analysis of the HepG2, Huh7, and SK-HEP-1 cells that
expressed HBx. According to these results, CCND1, a target of the
miR-16 family, was derepressed in HepG2-hbx cells. Next, we
confirmed that the induction of host c-Myc mediated the
suppression of miR-15a/16 in HepG2-hbx cells. Finally, we found
that ectopically expressed miR-15a/16 suppressed the prolifera-
tion, clonogenicity, and anchorage-independent growth of
HBx-expressing HepG2 cells by arresting cells in the G1 phase
and inducing apoptosis, while the miR-16 inhibitor promoted the
growth and cell-cycle progression of HepG2 cells.
MATERIALS AND METHODS
Cell culture
The human HepG2, SK-HEP-1, and Huh7 HCC cell lines were
purchased from American Type Culture Collection (ATCC,
Manassas, VA, USA) and cultured in Dulbecco’s modification of
Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS; HyClone, South Logan, UT,
USA). The cells were cultured in DMEM supplemented with 10%
FBS and 500ngml
 1 G418 (Invitrogen, Carlsbad, CA, USA)
(HepG2-hbx/HepG2-2.1, cells stably expressing HBx protein and
HepG2-vc, cells stably transfected with PCDNA3.1 plasmid) or
380ngml
 1 G418 (HepG2.2.15, HepG2 cells stably transfected with
the entire HBV genome). All cell lines were maintained in a
humidified atmosphere with 5% CO2.
RNA oligoribonucleotides and plasmids
The HBx open reading frame (Adr subtype, AB299858) was cloned
into the PCDNA3.1 (þ) plasmid (Invitrogen) to create PCDNA3.1-
hbx. All RNA oligoribonucleotides, including miR-15a/16 mimics/
inhibitors, c-Myc-specific siRNA, and negative control small RNAs
(NC), were purchased from GenePharma (Shanghai, China).
Cell transfection
RNA oligoribonucleotides and plasmids were transfected using
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s
instructions. 200 nM of miR-16 inhibitor and inhibitor NC, or 50
nM of other RNA oligoribonucleotides was used in cell transfec-
tion. For stable transfection, HepG2 cells were exposed to
900ngml
 1 G418 24h after transfection with PCDNA3.1-hbx or
PCDNA3.1. G418-resistant cells were further cultured to select the
HBx mRNA- and protein-expressing monoclones.
Reverse-transcription polymerase chain reaction and
qRT-PCR
Total RNA was extracted with TRIzol reagent (Invitrogen) and
treated with DNase I (Tiangen Biotech, Beijing, China). cDNA for
reverse-transcription polymerase chain reaction (RT-PCR) was
synthesised with the PrimeScript RT-PCR kit (Takara Biotechnology,
Dalian, China). The PCR amplification procedure for b-actin was
as follows: 941C for 3min; 30 cycles of 941C for 40s, 561C for 45s,
and 721C for 60s; followed by terminal elongation at 721C for
7min. The amplification of HBx was performed as follows: 951C
for 2min; 30 cycles of 951C for 30s, 62.51C for 30s, and 721C for
30s; followed by 721C for 5min. The qRT–PCR assays were
performed using the SYBR PrimeScript RT-PCR kit (Takara
Biotechnology). The assay kits for U6, miR-27a, miR-21,
miR-663, miR-15a, miR-15b, and miR-16 were purchased from
GenePharma; the TaqMan miRNA assay kit for miR-16 was
purchased from Ambion (Foster City, CA, USA). snoRNAs,
including RNU48, RNU44, U47, and RNU6B, were also purchased
from Ambion and used as endogenous controls.
Immunoblots
Cell cytosolic protein fractions were prepared using RIPA buffer
(Beyotime Biotechnology, Haimen, China). The antibodies used in
western blotting were HBx (sc-71239; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), b-actin (sc-130301; Santa Cruz), c-Myc
(9402; Cell Signaling Technology (CST), Boston, MA, USA),
CCND1 (2926; CST), and GAPDH (BA2913; Wuhan Boster
Biological Technology, Wuhan, China).
miRNA microarrays
The method for the miRNA microarray analysis was described in
our previous report, except for the addition of an updated miRNA
probe set (the NCode Human miRNA Microarray Probe Set V3þ,
Invitrogen) composed of 703 known and 393 predicted human
miRNAs in the present work (Yu et al, 2007).
Cell viability and apoptosis analysis
Cell proliferation was analysed with the Cell Counting Kit-8 (CCK-8;
Dojindo Laboratories, Kumamoto, Japan). The sphere formation
assay was performed by culturing the cells (1000 cellsml
 1)i n
suspension in serum-free DMEM-F12 supplemented with B27
(1:50, Invitrogen), 20ngml
 1 EGF (BD Biosciences, San Jose, CA,
USA), 0.4% bovine serum albumin (Sigma, St Louis, MO, USA),
and4mgml
 1 insulin (Sigma). For the clonogenicity analysis, 24h
after transfection, aliquots of 500 viable HepG2-hbx cells or 1000
viable HepG2.2.15 cells were placed in 6-cm dishes and maintained
in 10ml of complete medium for 2–3 weeks. Cell apoptosis was
determined 48h after the NC and miR-15a/16 mimic transfections
using an Annexin V-FITC kit (Bender MedSystems, Vienna,
Austria) and analysed using a BD FACSCalibur flow cytometer
(Becton Dickinson, San Jose, CA, USA).
Cell-cycle analysis
Twenty-four hours after the miRNA mimic and NC transfections,
the cells were treated with nocodazole (100ngml
 1, M1404;
Sigma) for 20h. Floating and adherent cells were harvested,
combined, washed once in phosphate-buffered saline, and fixed in
70% ethanol overnight. The DNA content was then examined using
the Cell Cycle Detection Kit (KGA512; KeyGen Biotechnology,
Nanjing, China) and analysed using BD FACSCalibur flow
cytometer.
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PGL3cm-CCND1-30UTR wild-type and pGL3cm-CCND1-30UTR
mutant vectors were received as generous gifts from Dr Shi-Mei
Zhuang (School of Life Sciences, Sun-Yat-sen University) and were
constructed as previously described (Xu et al, 2009). HepG2-hbx
and HepG2-vc cells were grown in 48-well plates and were co-
transfected with 2ng of pRL-TK (Promega, Madison, WI, USA)
and 5ng of wild-type or mutant luciferase reporter. Forty-eight
hours after transfection, the cells were harvested and subjected to a
luciferase assay. The firefly luciferase activity was normalised to
the Renilla luciferase activity.
The sequence of RNA and DNA oligoribonucleotides used can
be found in Supplementary Table 1.
RESULTS
Establishing the HepG2-hbx, HepG2-2.1 and HepG2-vc cell
lines
To investigate the impact of HBx on host miRNA expression in
HepG2 cells, we made stably expressing clones. We transfected the
HBx-expressing plasmid (HepG2-hbx or HepG2-2.1) or empty
vector (HepG2-vc) into the HepG2 cells and then performed G418
selection. Clones including HepG2-2.10 were screened for HBx
mRNA and protein expression (Figures 1A and B). Over time, the
expression of HBx increased the size and number of anchorage-
independent colonies in the HepG2-hbx cells to a greater degree
than in the HepG2-vc cells (Figures 1C and D).
Members of the miR-16 family were frequently suppressed
by HBx expression in HepG2, Huh7, and SK-HEP-1 cells
The miRNA microarrays were analysed to identify the HBx-
deregulated miRNAs in HepG2 cells. The results showed that of the
1096 miRNAs included in the assay, HBx caused widespread
suppressions of miRNA expression, including the miR-16 family,
in the HepG2-hbx cells compared with the HepG2-vc cells
(42-fold). Interestingly, few miRNAs, including miR-21, were
upregulated by HBx expression. Therefore, further studies will be
necessary to determine whether HBx impairs the biogenesis of
miRNAs in HepG2 cells (Kumar et al, 2007). The detailed results of
the microarray analysis are provided in Supplementary Table 2.
Because the miR-16 family has been reported to have multiple
roles in tumour suppression (Bonci et al, 2008), we used qRT-PCR
analysis to examine the expression of miR-16 family members in
HepG2 cells that had been stably or transiently transfected with
HBx. We found that the expression of these genes was significantly
suppressed in both stably and transiently transfected cells (Figures
2A and B). To eliminate the deviation induced by using RNU6B as
endogenous control, we further validated the HBx-mediated
downregulation of miR-16 in HepG2 cells using the TaqMan
miRNA assay, which was normalised to the means of the
endogenous controls, including RNU48, RNU44, U47, and RNU6B
(Supplementary Figure 1). To explore whether the HBx-mediated
repression of the miR-16 family was reproducible or restricted to
HepG2 cells, we transiently transfected PCDNA3.1-hbx and the
control vector into non-HBV-infected Huh7 and SK-HEP-1 cells.
Significantly, HBx also reduced the expression of the miR-16
family in both cell lines (Figures 2C and D). In confirmation of the
microarray results, we successfully detected the HBx-induced
downregulation of miR-27a/miR-663 and the upregulation of miR-
21 in HepG2 cells (Supplementary Figure 2).
To analyse whether the effects of HBx could be detected as far
downstream as the target genes of miR-16 family members, we
examined the expression of CCND1, a reported target of the
miR-16 family, which functions in the G1/S transition of the cell
cycle. Using a luciferase assay, we demonstrated that HBx
significantly upregulated the activity of the CCND1 30UTR in
HepG2-hbx compared with HepG2-vc cells (38±5%; Figure 2E).
Western blot results also confirmed the upregulation of CCND1 in
HBx-expressing HepG2 cells (Figure 2F). These results were in
accordance with reports that HBx stimulated cell-cycle progression
(Benn and Schneider, 1995) and activated the expression of CCND1
(Klein et al, 2003; Park et al, 2006; Jung et al, 2007).
In addition, we found that miR-16 exhibited an inverse
upregulation when HBx achieved pro-apoptotic doses during
transient transfection (Supplementary Figure 3). More apoptotic
cells appeared when we increased the dose of PCDNA3.1-hbx in
HepG2, Huh7, and SK-HEP-1 cells (data not shown). This finding
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(Terradillos et al, 1998; Arbuthnot et al, 2000) and miR-16 via the
targeting of BCL-2 (Cimmino et al, 2005). More studies are needed
to clarify the roles played by miR-16 in HBx-induced hepatocyte
apoptosis (or the inhibition of apoptosis) and acute/chronic HBV
infection.
Taken together, these results show that HBx causes global
miRNA deregulation in HepG2 cells and that the miR-16 family is
frequently repressed by HBx expression in HepG2, Huh7, and
SK-HEP-1 cells. Accordingly, CCND1, a target of the miR-16
family, is derepressed by HBx in HepG2 cells.
Loss-of-function of c-Myc restored the expression of
miR-15a/16 in HepG2-hbx cells
To elucidate the underlying mechanisms of HBx-induced miR-16
family downregulation, we referred to a previous report showed
that c-Myc repressed the promoter activity of pri-miR-15a/16-1 in
B-cell lymphomas (Chang et al, 2008). We examined the
expression of c-Myc in HepG2 cell lines stably transfected with
HBx. Consistent with others’ results (Balsano et al, 1991; Kalra and
Kumar, 2006; Li et al, 2010), HBx significantly upregulated
the mRNA and protein expression of c-Myc in HepG2 cells
(Figures 3A and B). As anticipated, the knock-down of c-Myc with
a specific siRNA produced a remarkable rescue of the expression
of miR-15a and miR-16 in HepG2-hbx cells at the indicated time
points (Figure 3C). Of note, miR-15a was more sensitive to
si-c-Myc treatment than was miR-16, which suggested that other
mechanisms may be involved in the regulation of miR-16. This
restoration could be reproduced in HepG2.2.15 cells (data not
shown). These results suggest that HBx downregulates miR-15a/16
expression, at least partly, through the induction of c-Myc in
HepG2 cells.
Reduced expression of miR-16 promoted the growth and
cell-cycle progression of HepG2 cells
Although the tumour-suppressive capacity of the miR-16 family
has been well documented in other cancers, a loss-of-function
assay was performed to determine the consequences of such
repression in HepG2 cells. We knocked down miR-16 expression
in HepG2 cells using a specific antisense inhibitor, and CCK-8
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Figure 2 HBx downregulates the expression of the miR-16 family in non-HBV-infected malignant hepatocytes in vitro and upregulates the expression of
CCND1 in HepG2 cells. (A) The expression of the miR-16 family was measured using qRT-PCR and normalised by U6 expression in HepG2 cells that stably
expressed HBx or control vector. (B–D) The expression of the miR-16 family normalised to U6 was detected by qRT-PCR in (B) HepG2, (C) Huh7, and
(D) SK-HEP-1 cells transiently transfected with HBx-expressing plasmid or control vehicle. Each cell line was transfected with 4mg PCDNA3.1-hbx or 4mg
PCDNA3.1 as a control. Cells were collected for analysis 48h after each transfection. (E) The activity of the luciferase reporter containing the wild-type
30UTR of CCND1 was elevated in HepG2-hbx cells. pRL-TK was co-transfected with a firefly luciferase reporter plasmid carrying either the wild-type (WT)
or mutant (MUT) 30UTR of CCND1 into HepG2-hbx or HepG2-vc cells; luciferase activity was analysed 48h later. pRL-TK expressing Renilla luciferase was
used to correct for the differences in transfection and harvest efficiencies between the HepG2-hbx and HepG2-vc cells. The ratio of the luciferase activity of
MUT-30UTR in HepG2-hbx to that in HepG2-vc cells was normalised to 1. (F) A western blot confirmed the induction of CCND1 by HBx in HepG2 cells.
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cell proliferation at 48, 72, and 96h post-transfection compared
with the NC transfectants (Figure 4A). miR-16 inhibition also
accelerated the G1/S transition in HepG2 cells (Figure 4B). The
efficiency of the inhibitor was checked by qRT-PCR analysis
(Supplementary Figure 4).
Ectopically expressed miR-15a/16 suppressed the
proliferation, clonogenicity, and anchorage-independent
growth of HBx-expressing HepG2 cells by arresting cells
at the G1 phase and inducing apoptosis
To inspect the therapeutic potential of the miR-16 family in HBV
þ
HCC, a series of in vitro experiments were performed. CCK-8
analysis showed that miR-15a/16 mimics repressed the growth of
HepG2-hbx cells at 72 and 96h post-transfection compared with
NC-transfected cells (Figure 5A). Subsequently, HepG2-hbx and
HepG2.2.15 cells were transfected with NC or miR-15a/16 mimics
and were allowed to form foci at a low density. Notably, fewer
colonies were seen in miR-15a/16 mimic-transfected HepG2-hbx
and HepG2.2.15 cells compared with NC transfectants (Figure 5B).
We further analysed the effects of miR-15a/16 on anchorage-
independent growth in a serum-free medium. The results showed
that miR-15a/16 expression in HepG2-hbx cells significantly
reduced the size and number of the spheres compared with the
NC transfectants (Figures 5C and D).
Next, we explored the mechanisms of the reduced survival of
HepG2-hbx cells treated with miR-15a/16 mimics. Fluorescence-
activated cell sorting results showed that the enforced expression
of miR-15a/16 caused an accumulation of cells during the G1 phase
in HepG2-hbx cells (Figure 5E). Moreover, miR-15a/16 mimics also
induced significantly more apoptotic cells than NC transfectants in
HepG2-hbx cells (Figure 5F). Collectively, these results illustrate
that the miR-16 family could efficiently repress the proliferation
and viability of HepG2-hbx cells by blocking cell-cycle progression
and inducing apoptosis.
DISCUSSION
Hepatitis B virus X protein alters the expression of the host
protein-coding genes by its transactivating function, thus con-
tributing to the initiation and progression of HCC. However, most
human genome transcripts are ncRNAs, including miRNAs, small
RNAs, and long ncRNAs, all of which have been confirmed to be
capable of regulating gene expression. The dysregulation of
miRNAs and long ncRNAs is extensively involved in many human
disease processes, including tumourigenesis (Matouk et al, 2007;
Mercer et al, 2009; Wilusz et al, 2009; Gupta et al, 2010). At
present, there have been few publications regarding the associa-
tions between HBx and host cellular miRNAs. In this study, we
demonstrated that HBx altered host miRNA expression in
malignant hepatocytes in vitro, including the c-Myc-mediated
downregulation of miR-15a/16. Loss- and gain-of-function assays
indicated the significance of miR-16 family deregulation in HepG2
cells transformed in vitro.
Hepatitis B virus X protein was found to cause widespread
suppression of miRNAs expression, including the miR-16 family,
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Figure 3 HBx suppresses the expression of miR-15a/16 by activating c-Myc in HepG2 cells. (A) qRT-PCR and (B) representative western blot results
showed that HBx upregulated c-Myc transcription and translation in HepG2 cells. Relative c-Myc expression was normalised to b-actin and GAPDH. The
qRT-PCR data are presented as mean±s.e. fold compared with HepG2-vc (n¼3, Student’s t-test). The c-Myc/GAPDH ratio is listed for the western blots.
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sin HepG2 cells, but the upregulation of only a few miRNAs. This
miRNA expression pattern is considered to be a specific
characteristic of tumours (Bottoni et al, 2005; Calin and Croce,
2006; Kumar et al, 2007). The downregulation of miR-15a, -16,
-338, and -422a has also been reported by Liu et al (2009). They
identified HBV-associated miRNAs differentially expressed
between HepG2.2.15 and the parental HepG2 cells using micro-
arrays and northern blot analyses. In the present study, we directly
transfected HBx into HepG2 cells to establish clones that stably
expressed HBx and demonstrated that the expression of the
miR-16 family was downregulated in HepG2 cells and HepG2.2.15
cells (Figure 2A). However, HepG2.2.15, which is a HepG2 cell line
transfected with a plasmid carrying four 50–30 tandem copies of
the HBV genome, still did not completely simulate natural HBV
infection, as multiple copies of HBV DNA were integrated into the
stably transfected line (Sells et al, 1987). This is likely to influence
cell function, and the role of the miR-16 family in HBV infection
in vivo remains to be further investigated.
The miR-16 family is composed of miR-15a, -15b, and -16. The
miR-15a/16-1 and miR-15b/16-2 gene clusters are located on
human chromosomes 13q and 3 and are co-transcribed with
DLEU2 and SMC4, respectively (Yue and Tigyi, 2010). This family
generally functions as a key regulator of the G1/S cell-cycle
checkpoint by targeting CCND1-3, CCNE1, and CDK6 (Linsley
et al, 2007; Liu et al, 2008). Accordingly, the deletion of 13q (the
location of miR-15a/16-1) is associated with the deregulation of
genes involved in the cell cycle and proliferation in dediffer-
entiated HCCs (Skawran et al, 2008) and is also related to
aggressive HCC behaviours (Wong et al, 2002). This family has
also been shown to be repressed and to suppress (in specific
tumour types) a series of oncogenes that include c-Myb, Bmi-1,
BCL-2, WNT3A, and Wip1 (Bottoni et al, 2005; Cimmino et al,
2005; Bonci et al, 2008; Bandi et al, 2009; Bhattacharya et al, 2009;
Zhao et al, 2009; Zhu et al, 2009; Klein et al, 2010; Meyer-Rochow
et al, 2010; Zhang et al, 2010). Moreover, members of the miR-16
family are involved in regulating chemosensitivity (Blower et al,
2008; Xia et al, 2008). With respect to HCC, the downregulation of
miR-15a and miR-16-1 is a valuable predictor of HCC venous
metastasis and patient survival (Budhu et al, 2008). High
expression of miR-15b is correlated with a low risk of tumour
recurrence following hepatectomy (Chung et al, 2010). In addition
to hepatocytes, miR-15b and miR-16 are repressed during the
activation of rat hepatic stellate cells (HSCs; Guo et al, 2009b), and
miR-16 inhibits proliferation while increases the apoptosis of HSCs
(Guo et al, 2009a). Importantly, HBx can induce paracrine
activation and proliferation of HSCs in both human and rat liver
via TGF-b (Martin-Vilchez et al, 2008). Collectively, these data
suggest that the suppression of the miR-16 family contributes to
the initiation (i.e., liver fibrosis/cirrhosis) and progression of HBV/
HBx-induced HCCs.
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sThe miR-16 family is the downstream target of several
oncogenic and tumour suppressor networks. p53 facilitates the
maturation of the miR-15a/16-1 cluster (Suzuki et al, 2009), and
the expression of miR-15b/16-2 cluster is directly induced by E2F1
and E2F3 during the G1/S transition (Bueno et al, 2010). Radiation
also induces the upregulation of miR-15a/16 in glioblastoma cells
(Chaudhry et al, 2010) and in human endothelial cells (Wagner-
Ecker et al, 2010). In contrast, the expression of the miR-16 family
has been shown to be suppressed 41.5-fold by c-Myc and lin28B
in B-cell lymphomas (Chang et al, 2008, 2009), which mirrors the
preliminary HBx-c-Myc-miR-15a/16 pathway found in our study.
c-Myc has been suggested to have a central role during the
malignant transition in human hepatocarcinogenesis (Kaposi-
Novak et al, 2009). Additionally, HER2 Delta 16 suppresses miR-
15a/16 and deregulates BCL-2 to promote endocrine resistance in
breast tumours (Cittelly et al, 2010), whereas PKC alpha down-
regulates miR-15a in head and neck squamous cell carcinoma
(Cohen et al, 2009). Notably, because HBx can antagonise the
function of p53 by itself (Dewantoro et al, 2006) or by recruiting
c-Myc (Lee and Rho, 2000), we propose that HBx may induce
c-Myc to repress the transcription and p53-mediated post-
transcriptional maturation of miR-15a/16.
While this manuscript was being prepared, Wang et al (2010)
reported for the first time that HBx induced the deregulation of
cellular miRNAs in HepG2 cells and that the let-7 family was
downregulated in both HBx-transfected cell lines and HBV-
infected HCC tumour tissue (Wang et al, 2010). The miR-16
family was not included in their microarray analysis; however, the
repression of let-7d (42-fold) was detected in our results. The
disparities between these data may have resulted from differences
in the HBx expression system (i.e., Wang et al employed a
transient recombinant adenovirus infection, whereas we used
stable transfection), differences in microarray sensitivity, and in
the intensity of HBx protein expression.
In conclusion, we found that HBx altered the expression of
cellular miRNAs in host malignant hepatocytes in vitro, including
the repression of the miR-16 family. Furthermore, HBx-induced
downregulation of miR-15a/16 in HepG2 cells was c-Myc mediated,
while ectopically expressed miR-15a/16 repressed the proliferation,
clonogenicity, and anchorage-independent growth of HepG2-hbx
cells by inducing cell-cycle arrest and apoptosis. Our results
highlight the therapeutic roles that targeting c-Myc and the miR-16
family may play in HBV-related chronic liver diseases.
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